ATP13A3

Across TCGA pan-cancer cohorts, ATP13A3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATP13A3 data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATP13A3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ATP13A3 expression acts as an unfavorable survival marker.

CCRCC, HNSC, and LUAD are the cancer types where ATP13A3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.740	0.916	.007	40	view →
HNSC	DFS	Median	III,IV	0.903	1.000	.004	35	view →
LUAD	OS	Quartile	II,III,IV	0.299	0.879	.008	13	view →
PDAC	DFS	Quartile	All	0.643	0.879	.022	7	view →
LSCC	DFS	Tertile	II,III,IV	0.400	1.000	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATP13A3–CCRCC (OS)

Open the CCRCC breakdown →